CN105982919A - Biological retarder anti-cancer technology - Google Patents

Biological retarder anti-cancer technology Download PDF

Info

Publication number
CN105982919A
CN105982919A CN201510088530.0A CN201510088530A CN105982919A CN 105982919 A CN105982919 A CN 105982919A CN 201510088530 A CN201510088530 A CN 201510088530A CN 105982919 A CN105982919 A CN 105982919A
Authority
CN
China
Prior art keywords
biological
moderator
cancer
retarder
bifidobacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510088530.0A
Other languages
Chinese (zh)
Inventor
王汉成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201510088530.0A priority Critical patent/CN105982919A/en
Publication of CN105982919A publication Critical patent/CN105982919A/en
Pending legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

In order to solve the high-speed cancer excited state problem, a biological retarder is needed. Cancer energy is converted into intramolecular transfer or other vibrational state transfer through collision. By means of the nucleus retarder principle, a neutron and a retarder atomic nucleus are subjected to collision so that the speed can be decreased, and the retarder which does not absorb neutrons and does not react with neutrons is selected. An important task of the cancer biology and even the natural science is that which material can bear a cancer nuclear fission biological retarder. According to repeated experiments, various safety factors are synthesized, and finally a biological moderator is correctly selected through a successful experiment. Bifidobacterium is free of toxicity and harm to a body, and the biological retarder can be ideal for treating a cancer. In the future, more microorganism retarders will be produced, the biological retarder is used for decelerating tumors, a proper amount of deceleration molecular nuclear energy can be used as senile cell addition nuclear energy, and the biological retarder gives power to biological science and will play an indispensable critical role.

Description

Biological moderator anti-cancer technology
Technical field
The mankind explore the time that cancer has gone through century more than one, but the lethal challenge of cancer but remains unchanged, and become current natural section highlightedly Learn great difficult problem.Although cancer problem affects the heart of " millions of people, scientists is also racked one's brains, and manages to disclose its very crux, but for a long time with Do not obtain essence to break through.Cancer cell dyskaryosis, cell is inmature, anaplastic.High nucleocytoplasmic ratio, the fever phenomenon of unknown cause and uranium Feature, nucleocytoplasmic ratio during nuclear fission, mass deficit, abnormal huge energy etc., have perfectly in harmony surprising identical.Microcosmic atomic nucleus is anti- Should be closely bound up with macroscopic material evolutionary process, cancer cell nuclear fission " supernova outburst " nuclear fission famous with nuclear fission phenomenon, universe, Of an identical nature, it is the physics basic law of coincidence or own profound?Cancer cell nuclear fission is no biological minor matters phenomenon, may be potential natural Unity of sciences rule.Nuclear division physical image word starts from uranium nuclei the earliest and is broken into two almost equal parts ... this situation with Biologically the fission process of cell proliferation is closely similar, and this makes us have reason this phenomenon to be referred to as ' nuclear fission ' ".Split by microcosmic uranium nuclei Change to cosmoscopic neutron star nuclear fission, finally revert to the successful description of molecule cancer cell nuclear fission event.Cancer cell nuclear fission discloses cosmoscopic core deeply Comprehensive uniformity in biological gene for the synthesis mechanism.Represent on molecular biosciences level again and developed Einstein's mass-energy relation E=mc2. Cancer is exactly nucleus fission one nuclear physics basic law.
Background technology
Four big spectrum (purple, glimmering, red, Raman) spectrum two-dimensional excitation information confirm;Cancer substance spectra absorption blue-shift shows that the sub-state of cancer amount of DNA has higher Energy level
Between the extent of polymerization of modern apparent genetics research discovery oncogene and spatial configuration and normal structure, there is significant difference.Cancer cell DNA is purple Outer line absorption top aspect all compared with normal tissue DNA absworption peaks and trend towards blue-shifted phenomenon, oncogene, cancer RNA, oncoprotein suffers from Above-mentioned DNA excites molecule blue shift specific phenomenon, and this means that there is quantum specific genetic phenomenon in DNA secondary structure, and this is no minor matters Phenomenon.And it is finally possible to related with quantum genetics general principle to biological quantum mechanics.The nucleoprotein ultraviolet radiation absorption of oncogene strong bonded is Peak moves 5-8 millimicron to shortwave aspect, quite mutually with energy be every gram molecule be 2-3 thousand card, similar complex fastness and Hard-decomposed, oncogene excitation state quantum all depends on this.Cancer cell Embryo, oncogene high polymeric and overall DNA molecular structure with And DNA excited electronic state is relevant.
In the β decay process of atom, the time of abundance is had to allow unstable nuclear synthesis.Same in the cell differentiation procedure in life very long years, cell Replicate the homoatomic β decay processes such as differentiation.Having the time of abundance, it is allowed to have unstable nucleus to be polymerized, it is exactly that nucleus closes that cancer is dedifferented The change procedure becoming.Biological normal cell is one and replicates the stable balance system of differentiation, due to the change of surrounding environment or by extraneous active force And becoming the cancer cell of nonequilibrium condition, the process that this cell is transitioned into new cell balance state from nonequilibrium condition again is known as canceration, and it is borrowed The DNA relaxation process releasing energy with continuous duplication.Canceration relaxation process substantially cancer cell is for positive energy exchange and the microcosmic in biosystem Particle interacts, until reaching the distributed process of stable isotope cell.Cancer cell replicates persistence, it is impossible to controlling.Also it is not just difficult to Reason with somebody.
Content of the invention
Molecular relaxation is a kind of physical phenomenon, be vibrational excitation molecule can by energy at intramolecular transfer to other vibrational state, or turn to rotational and Translation energy, or produce fluorescence, or it is converted into translation energy through collision, or pass to another molecule.Molecular relaxation refers to molecule by a kind of excitation state transition The excitation state relatively low to another energy or the process of ground state.Relaxation has various ways.For example, the molecular energy of electron excitation is relatively big, can be directly by electricity Sub-excitation state jumps back ground state, produces fluorescence: can be gone to triplet T by singlet state S1, then jump to low state S0 from triplet T, produce phosphorescence simultaneously; Also can transfer the energy to vibration level in S1 state and rotate level, then with mode anergies such as fluorescence;Also can by collision energy become kinetic energy or It is transferred to another molecule etc..The molecule of vibrational excitation can by energy at intramolecular transfer to other vibrational state, or turn to rotational and translation energy, Or generation fluorescence, or it is converted into translation energy through collision, or pass to another molecule etc..Relaxation is not instantaneous i.e. to die, so excitation state has one Fixed life-span, referred to as relaxation time.The macroscopic law of relaxation process is decided by the character that in system, microcosmic particle interacts.Therefore, cancer base is studied Because of relaxation phenomena be release cancer DNA excited electronic state, return stablize ground state can not by replicate decay process, and be intended to by intermolecular collision by DNA energy becomes kinetic energy or is transferred to another molecule, and this is only one of radical cure most effective approach of cancer.
For releasing cancer DNA hydrogen electronics highly excited level, come in the urgent need to a kind of biological moderator of development, by collision, cancer DNA energy is become molecule It is inside transferred to other vibrational state transfer energy.Use for reference decelerating atoms agent principle;The neutron of these rapid movements must occur core anti-being absorbed by nuclear fuel Before should slow down movement velocity, usual way is to use moderator, i.e. neutron and the atomic nucleus of moderator collides and make speed reduce, choosing Select the condition of moderator be neither absorb neutron and also with neutron generation nuclear reaction, they can be heavy water, graphite, carbon dioxide or light-water (i.e. The very high light water of purity).By numerous experiments, we determine that biological moderator is unlikely to be heavy water, graphite, water, but they must be containing slowly The proton of change effect is formed, the correct selection of biological moderator of the final Success in Experiment of comprehensive multiple safety factors.
Detailed description of the invention
Which kind of material can undertake cancer cell nuclear fission DNA, the biological moderator task of protein hydrogen electronics high speed excitation state material?This is knubble biological Learning or even a Materiality problem in natural science being around this problem, first we be the foundation having passed through the theory of knowledge (philosophy of biology);Biological substance Non-physical material, biological moderator and immaterial heavy water, graphite, water moderator, there is its unique forms though biological but be all physics basic law institute Can summarize.These understanding let us turn to bioprotein, nucleic acid hydrogen bonds group notice from material moderator, for biological moderator structure Discovery lay a good foundation then pass through primary fine thalline;Bacteriophage and Escherichia coli set up experiment.Results are to good biological moderator effect. Natural the showing at 255-256 millimicron of cancer HeLa cell ultraviolet spectrogram absworption peak as embryonic cell.Biological by Escherichia coli After moderator, HeLa cell revert to normal cell direction, at ultraviolet spectra absworption peak curve 260 millimicrons.Establish biology for oncotherapy Moderator experimental model. Current antineoplastic mechanism to Bifidobacterium is it is believed that be mainly by strengthening the immunologic function of host, particularly activating macrophage, NK Cell and bone-marrow-derived lymphocyte, and promote that these effector cells discharge immunity substance, such as 1L-1, IL-6,1L-12, TNF-Q, IFN -Y, NO etc., thus play indirectly antitumor action;And also can the apoptosis of direct induced tumor cell.Also scholar is had to test discovery bifid bar The DNA of bacterium also has antitumor action.Bifidobacterium has as the advantage of oncotherapy carrier, does not produce drug resistance, can successive administration;Without bright Aobvious toxic and side effect, can be used for the treatment of various entity tumor;Bifidobacterium has the advantages such as targeting is good, toxic and side effect is little, therefore, is a kind of reason The gene therapy vector thought.But, the research in terms of current Bifidobacterium molecular biology is less, and Bifidobacterium is applied to grinding of therapy of tumor Study carefully and be still in the starting stage, the security etc. of Bifidobacterium transformant.Some more basic problems not yet really solve.
Bifidobacterium is nontoxic to body, therefore can treat tumour as one preferably biological moderator preparation. make biological deceleration with Bifidobacterium Agent, in addition to itself antitumor action, provides a new thinking for the treatment of slowing down of the excitation state of tumour, for oncotherapy bring one new Revolution.After biological moderator experiment, it was demonstrated that Bifidobacterium is ideal biological moderator, process to HeLa cell, breast cancer cell, It after tumour blood of patients with lung cancer, serum deceleration are processed, all successfully revert to 260,279/252nm normal cell spectral absorbance values direction.
The boundless universe.There is no lack of strange things.Bacterium, to live many seeds of trouble being considered as by people and causing a disease, is but used as cancer cell nuclear fission now and virus is quick Attenuated vaccine produce biological moderator preparation, e. coli k12, MG1665, engineering bacteria DH5 α and JM109 these will not germ and The preferably biological moderator such as Bifidobacterium, antitumor, will make them be more widely used in antiviral field.It is expected that in the present After years in, also will have more microorganism moderator preparation and be born, and will be applied more broadly in medical treatment and the field such as health care.Biological deceleration Agent can be slowed down for tumour cell, and the appropriate cell nuclear energy slowing down can be used as senile cell and adds nuclear energy, and biological moderator is that life science is further strengthened, To there is indispensable key effect.

Claims (3)

1. use for reference atomic nucleus moderator principle;For releasing cancer DNA high speed excitation quantum state, come in the urgent need to developing a kind of biological moderator, by collision, cancer DNA excitation state is changed into intramolecular excitation energy and shifts, or to the transfer of other vibrational state energy.Thus a kind of biological moderator principle of development and method.Any this principle of use and method produce biological moderator preparation and its anti-cancer technology.
2. antitumor, e. coli k12, MG1665 in antiviral field, engineering bacteria DH5 α and JM109 these will not germ and Bifidobacterium etc. be preferable biological moderator, also will have more microorganism moderator preparation and be born, this will make them be more widely used.Any to treat neoplastic disease, the biological moderator of production application for the purpose for the treatment of virosis.
3. especially Bifidobacterium is nontoxic to body, and Bifidobacterium has the advantages such as targeting is good, toxic and side effect is little, and therefore, you can be a kind of preferable gene therapy vector.Can be used for the treatment of various entity tumor.But your not handy Bifidobacterium makees biological moderator application;Shift for tumour energy or carry out treatment of slowing down, using Bifidobacterium as biological moderator anti-cancer technology.
CN201510088530.0A 2015-02-26 2015-02-26 Biological retarder anti-cancer technology Pending CN105982919A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510088530.0A CN105982919A (en) 2015-02-26 2015-02-26 Biological retarder anti-cancer technology

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510088530.0A CN105982919A (en) 2015-02-26 2015-02-26 Biological retarder anti-cancer technology

Publications (1)

Publication Number Publication Date
CN105982919A true CN105982919A (en) 2016-10-05

Family

ID=57037823

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510088530.0A Pending CN105982919A (en) 2015-02-26 2015-02-26 Biological retarder anti-cancer technology

Country Status (1)

Country Link
CN (1) CN105982919A (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10322151B2 (en) 2015-06-15 2019-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10391128B2 (en) 2015-11-23 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10391130B2 (en) 2015-06-15 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
CN110361345A (en) * 2018-04-11 2019-10-22 魏秋英 Ultraviolet spectra DNA protein phenotypic analysis instrument
US10456444B2 (en) 2014-12-23 2019-10-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10471108B2 (en) 2015-11-20 2019-11-12 4D Pharma Research Limited Compositions comprising bacterial strains
US10485830B2 (en) 2016-12-12 2019-11-26 4D Pharma Plc Compositions comprising bacterial strains
US10493112B2 (en) 2015-06-15 2019-12-03 4D Pharma Research Limited Compositions comprising bacterial strains
US10500237B2 (en) 2015-06-15 2019-12-10 4D Pharma Research Limited Compositions comprising bacterial strains
US10583158B2 (en) 2016-03-04 2020-03-10 4D Pharma Plc Compositions comprising bacterial strains
US10610548B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Compositions comprising bacterial strains
US10610550B2 (en) 2015-11-20 2020-04-07 4D Pharma Research Limited Compositions comprising bacterial strains
US10736926B2 (en) 2015-06-15 2020-08-11 4D Pharma Research Limited Compositions comprising bacterial strains
US10744166B2 (en) 2015-11-23 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10851137B2 (en) 2013-04-10 2020-12-01 4D Pharma Research Limited Polypeptide and immune modulation
US10987387B2 (en) 2017-05-24 2021-04-27 4D Pharma Research Limited Compositions comprising bacterial strain
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11013773B2 (en) 2011-07-14 2021-05-25 4D Pharma Research Limited Lactic acid bacterial strains
US11123378B2 (en) 2017-05-22 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
US11723933B2 (en) 2014-12-23 2023-08-15 Cj Bioscience, Inc. Composition of bacteroides thetaiotaomicron for immune modulation

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11013773B2 (en) 2011-07-14 2021-05-25 4D Pharma Research Limited Lactic acid bacterial strains
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
US11414463B2 (en) 2013-04-10 2022-08-16 4D Pharma Research Limited Polypeptide and immune modulation
US10851137B2 (en) 2013-04-10 2020-12-01 4D Pharma Research Limited Polypeptide and immune modulation
US11723933B2 (en) 2014-12-23 2023-08-15 Cj Bioscience, Inc. Composition of bacteroides thetaiotaomicron for immune modulation
US10456444B2 (en) 2014-12-23 2019-10-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10973872B2 (en) 2014-12-23 2021-04-13 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10736926B2 (en) 2015-06-15 2020-08-11 4D Pharma Research Limited Compositions comprising bacterial strains
US10322151B2 (en) 2015-06-15 2019-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10493112B2 (en) 2015-06-15 2019-12-03 4D Pharma Research Limited Compositions comprising bacterial strains
US11273185B2 (en) 2015-06-15 2022-03-15 4D Pharma Research Limited Compositions comprising bacterial strains
US11040075B2 (en) 2015-06-15 2021-06-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10391130B2 (en) 2015-06-15 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10500237B2 (en) 2015-06-15 2019-12-10 4D Pharma Research Limited Compositions comprising bacterial strains
US11331352B2 (en) 2015-06-15 2022-05-17 4D Pharma Research Limited Compositions comprising bacterial strains
US10744167B2 (en) 2015-06-15 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US11389493B2 (en) 2015-06-15 2022-07-19 4D Pharma Research Limited Compositions comprising bacterial strains
US10780134B2 (en) 2015-06-15 2020-09-22 4D Pharma Research Limited Compositions comprising bacterial strains
US11433106B2 (en) 2015-06-15 2022-09-06 4D Pharma Research Limited Compositions comprising bacterial strains
US10864236B2 (en) 2015-06-15 2020-12-15 4D Pharma Research Limited Compositions comprising bacterial strains
US10610550B2 (en) 2015-11-20 2020-04-07 4D Pharma Research Limited Compositions comprising bacterial strains
US10471108B2 (en) 2015-11-20 2019-11-12 4D Pharma Research Limited Compositions comprising bacterial strains
US11058732B2 (en) 2015-11-20 2021-07-13 4D Pharma Research Limited Compositions comprising bacterial strains
US10744166B2 (en) 2015-11-23 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10391128B2 (en) 2015-11-23 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10583158B2 (en) 2016-03-04 2020-03-10 4D Pharma Plc Compositions comprising bacterial strains
US10960031B2 (en) 2016-07-13 2021-03-30 4D Pharma Plc Compositions comprising bacterial strains
US10967010B2 (en) 2016-07-13 2021-04-06 4D Pharma Plc Compositions comprising bacterial strains
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
US10610549B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Composition comprising bacterial strains
US10610548B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Compositions comprising bacterial strains
US10898526B2 (en) 2016-12-12 2021-01-26 4D Pharma Plc Compositions comprising bacterial strains
US10543238B2 (en) 2016-12-12 2020-01-28 4D Pharma Plc Compositions comprising bacterial strains
US10485830B2 (en) 2016-12-12 2019-11-26 4D Pharma Plc Compositions comprising bacterial strains
US11123378B2 (en) 2017-05-22 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11376284B2 (en) 2017-05-22 2022-07-05 4D Pharma Research Limited Compositions comprising bacterial strains
US11382936B2 (en) 2017-05-22 2022-07-12 4D Pharma Research Limited Compositions comprising bacterial strains
US10987387B2 (en) 2017-05-24 2021-04-27 4D Pharma Research Limited Compositions comprising bacterial strain
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11660319B2 (en) 2017-06-14 2023-05-30 4D Pharma Research Limited Compositions comprising bacterial strains
US11779613B2 (en) 2017-06-14 2023-10-10 Cj Bioscience, Inc. Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
CN110361345A (en) * 2018-04-11 2019-10-22 魏秋英 Ultraviolet spectra DNA protein phenotypic analysis instrument

Similar Documents

Publication Publication Date Title
CN105982919A (en) Biological retarder anti-cancer technology
Atzeni et al. Shock ignition of thermonuclear fuel: principles and modelling
TWI572389B (en) Instrument set and system for producing change in medium, system for generating light or curing, radiation-cured or curable article, microwave or rf receptor, and system for treatment or diagnosis
Pitkänen Cold fusion, low energy nuclear reactions, or dark nuclear synthesis
CN104321827A (en) Apparatus and method for generating medical isotopes
Soker The role of jets in exploding supernovae and in shaping their remnants
AU2015300961B2 (en) High efficiency neutron capture products production
Abbas et al. Development of an accelerator driven neutron activator for medical radioisotope production
Cheng et al. Hitherto‐Unexplored Photodynamic Therapy of Ag2S and Enhanced Regulation Based on Polydopamine In Vitro and Vivo
Gavrilyuk Hydrogen energy for beginners
Gonzales et al. Ultra-low fluence rate photodynamic therapy: simulation of light emitted by the Cerenkov effect
Hossain et al. Shallow folding potential for 16O+ 12C elastic scattering
US20100268012A1 (en) Radioprotective materials, methods of transport and utilization thereof, nanoscale-microscale supramagnetic and supraconducting particles, spherical flow dynamics and sonoluminesence
Ikeda et al. Fabrication of high-concentration Cu-doped deuterated targets for fast ignition experiments
Jin-Gen et al. Proton halo or skin in the excited states of light nuclei
Kudri︠a︡shov Radiation Biophysics (Ionizing Radiations)
Yao et al. Isoscaling behavior studied by HIPSE model
Reisenegger Neutron stars and their magnetic fields
Bouchet et al. The use of synchrotrons in SFRT and FLASH therapy
Purohit et al. Boron neutron capture therapy: History and recent advances
Meesat et al. Filamentation of femtosecond laser pulses as a source for radiotherapy
Schatz Anniversaries: 2000
Cai et al. Endohedral Clusterfullerenes: Future Perspectives
Liu et al. Theoretical study on intramolecular hydrogen transfer involving amino-substituted perylenequinone
Lebedev et al. Structures of Nanodiamonds with Photoactive Modifiers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20161005

RJ01 Rejection of invention patent application after publication